Aclaris Therapeutics Files 8-K on Shareholder Vote

TL;DR

ACRS filed an 8-K for a shareholder vote on June 6th.

AI Summary

Aclaris Therapeutics, Inc. filed an 8-K on June 7, 2024, reporting on a matter submitted to a vote of its security holders on June 6, 2024. The filing details the company's corporate information, including its principal executive offices in Wayne, PA, and its standard industrial classification as Pharmaceutical Preparations.

Why It Matters

This filing indicates a significant corporate event involving a shareholder vote, which could impact the company's governance and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes or operational risks.

Key Players & Entities

• Aclaris Therapeutics, Inc. (company) — Registrant
• June 6, 2024 (date) — Date of earliest event reported
• June 7, 2024 (date) — Date of report
• Wayne, PA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.00001 — ange on which Registered Common Stock, $0.00001 par value ACRS The Nasdaq Stock Mar

Filing Documents

• acrs-20240606x8k.htm (8-K) — 52KB
• 0001558370-24-009009.txt ( ) — 170KB
• acrs-20240606.xsd (EX-101.SCH) — 3KB
• acrs-20240606_lab.xml (EX-101.LAB) — 16KB
• acrs-20240606_pre.xml (EX-101.PRE) — 10KB
• acrs-20240606x8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 6, 2024, Aclaris Therapeutics, Inc. (the " Company ") held its 2024 annual meeting of stockholders (the " Annual Meeting "). The stockholders considered three proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2024 (the " Proxy Statement "). Of the 71,264,786 shares outstanding as of the record date, 57,788,889 shares, or 81.09%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting. Proposal No. 1 : The stockholders elected two nominees to serve as directors on the Board of Directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld Broker Non-Votes Christopher Molineaux 29,165,764 16,154,877 12,468,248 Vincent Milano 42,267,754 3,052,887 12,468,248 Proposal No. 2 : The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: Votes For Votes Against Abstained Broker Non-Votes 29,025,583 16,273,816 21,242 12,468,248 Proposal No. 3 : The stockholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024. The votes were cast as follows: Votes For Votes Against Abstained 56,610,643 1,154,624 23,622

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ACLARIS THERAPEUTICS, INC. By: /s/ Kevin Balthaser Date: June 7, 2024 Kevin Balthaser Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR